Fresenius Kabi USA, LLC recalls Naropin
- Recalling company
- Fresenius Kabi USA, LLC
- Product
- Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05
- Reason
- Presence of Particulate Matter: Hair was found in products
- Classification
- Class II – may cause temporary or medically reversible health consequences
- Recall date
- Jul 16, 2026
- Reported
- Jul 29, 2026
- Distribution
- Nationwide within in the USA
- Status
- Ongoing
- Quantity
- 92,600 vials
- Lot / codes
- Lot #: 6133436, Exp. Date 10/2028
- Company location
- Lake Zurich, IL
- Recall type
- Voluntary: Firm initiated
- Recall number
- D-0727-2026
- Agency
- U.S. Food and Drug Administration (FDA)
View official FDA notice ↗ Search recall number D-0727-2026 in the FDA Enforcement Report. Also see FDA recall press releases.
If you use this product, check the lot, NDC or model number against the official notice and follow its instructions. Do not stop a prescribed medicine or remove a medical device without talking to your doctor or pharmacist. Report problems to FDA MedWatch. FoodRecallNow summarizes public FDA data and is not medical advice.